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Abstract
Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have 
a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. 
Surgery is the only potentially curative therapy in both cancers, but disease recurrence is frequent. In PC, adjuvant treat-
ment with mFOLFIRINOX has improved overall survival (OS) and in BTC adjuvant treatment with capecitabine seems to 
improve OS and relapse-free survival. Concomitant radio-chemotherapy could also be considered following R1 surgery in 
both neoplasms. Neoadjuvant treatment represents the best option for achieving an R0 resection in borderline PC. Upfront 
systemic chemotherapy is the treatment of choice in unresectable locally advanced PC and BTC; then locoregional therapy 
could be considered after an initial period of at least 3–4 months of systemic chemotherapy. In metastatic PC, FOLFIRINOX 
or Gemcitabine plus nab-paclitaxel have improved OS compared with gemcitabine alone. In metastatic BTC, cisplatin plus 
gemcitabine constitute the standard treatment. Progress in the knowledge of molecular biology has enabled the identifica-
tion of new targets for therapy with encouraging results that could in the future improve the survival and quality of life of 
patients with PC and BTC.
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Methodology
The present guidelines have been based on the relevant 
studies published and with the consensus of the all authors. 
In order to assess the level and quality of evidence and to 
establish a grade of recommendation of the different state-
ments in this guideline, we based ourselves on The Infec-




Pancreatic ductal adenocarcinoma (PDAC) is the third cause 
of death by cancer at the European Union. It will become the 
second during the next 10 years. Only 5% of PDAC patients 
survive 10 years. Its incidence is raising and is usually diag-
nosed at an advanced stage due to its particular aggressive 
biology and non-specific symptoms [1]. Only 15–20% of 
patients are candidates for surgery at presentation and two 
thirds of them recur. Treatment usually consists of chem-
otherapy combinations with no targeted agents available. 
There is a desperate need for an earlier diagnosis to identify 
the population at a higher PDAC risk for developing primary 
and secondary prevention programs, a better policy making 
and for effective medical treatments. Patients diagnosed with 
PDAC should undergo an assessment of risk for hereditary 
syndromes known to be associated with an increased risk for 
pancreatic adenocarcinoma.
Epidemiology and risk factors
Age, tobacco smoking, alcohol consumption, overweight, 
new onset diabetes, pancreatitis, etc. are associated with 
a slight increase in the incidence of PDAC. Familial can-
cer with pathogenic germline alterations (BRCA1, BRCA2, 
ATM, PALB2, MLH1, MSH2, MSH6, PMS2, CDKN2A, P53 
and others still unknown), which involves 10% of the whole 
PDAC patients, is the only established high-risk population. 
Integration of omics data with clinical factors could design a 
signature for PDAC risk scores. A blood-based early diagno-
sis in the high-risk subgroup is the most promising approach.
Diagnosis
A PDAC-oriented CT scan may show a pancreatic mass in 
most of cases. When the tumor is iso-dense with the stroma, 
an MRI is needed. More than 50% of PDAC pathology 
diagnosis is performed from a fine needle aspiration (FNA) 
cytology of the primary tumor, with no architectural tissue 
features, in cancer with a dense stroma. Diagnosis accurate-
ness could be improved by a Tru-cut needle biopsy obtained 
from a liver metastasis, at the surgery of the primary tumor 
or through a thick-enough trans-duodenal biopsy.
Molecular biology
Pre-neoplastic lesions (cystic tumors, intraductal papillary-
mucinous neoplasms -IPMN, and pancreatic intraepithelial 
neoplasia-PanIN) show different carcinogenic pathways 
conditioned by the cell of origin and the genetic and micro-
environment alterations observed. They should be classified 
according to imaging features and novel biomarkers.
The original cell giving rise to PDAC is controversial as 
some acinar cells can experience acinar to ductal metapla-
sia (ADM) under stress conditions. KRAS mutations make 
the pancreatic ductal cells as well as these ADM cells to 
remain ductal, upregulate EGFR signaling, and progress to 
PanIN1. The evolution to PanIN2 needs additional muta-
tions in tumor suppressor genes like CDKN2A. Inactivation 
of other suppressor genes like SMAD4, BRCA2, TP53, etc. 
occurs at PanIN3 or high-grade dysplasia, considered as 
carcinoma in situ, and in PDAC. After BRG1 inactivation, 
KRAS mutated duct cells may also progress to IPMN and 
some of them to invasive IPMN or PDAC through consecu-
tive gene alterations.
Cellular heterogeneity is shown in preneoplastic lesions. 
Cellular plasticity at early stages is corroborated by their 
presence in the circulation and at secondary organs before 
progression to carcinoma [2].
In parallel, the microenvironment converts to proinflam-
matory, there is a crucial crosstalk with cancer cells favoring 
the development of preneoplastic lesions and finally PDAC 
in a desmoplastic, fibrotic, and immune-suppressive stroma 
with a loose vasculature and poor tumor perfusion leading 
to hypoxia and suboptimal drug and immune cells entrance.
The most common driver mutated genes in PDAC are 
KRAS, TP53, CDKN2A and SMAD4. Unfortunately, these 
pathways are still not therapeutically targeted. Epigenetic 
changes and metabolic rewiring are related to metastatic 
behavior.
Tumor-associated macrophages (TAM-M2), cancer-asso-
ciated fibroblasts (CAF) Tregs and myeloid-derived suppres-
sor cells (MDSCs) inhibit the immune.
Transcriptomics classify PDAC in basal-cell tumors, also 
called squamous, which survive shorter than the classic sub-
types (immunogenic, pancreatic progenitor and ADEX) [3]. 
Low GATA6 expression [4] and high KRT14 or KRT5/6 [5] 
are surrogate biomarkers of basal-cell tumors that are less 
differentiated and associated with an activated stroma. They 
may respond better to gemcitabine-nab-paclitaxel than to 
FOLFIRINOX while classical type tumors respond better to 
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FOLFIRINOX. Serine hydrolase carboxylesterase 2 (CES2) 
is predictive of response to irinotecan as mediates its intra-
tumoral activation. It is associated with type 2 diabetes [6].
The digestive microbiome has demonstrated multiple 
effects on tumor biology, and bacteria, mostly located intra-
cellularly in both cancer and immune cells, may be related 
to the different phenotypes and on their interaction with the 
immune system [7].
Staging
After a suspicion of pancreatic cancer (weight loss, jaun-
dice, pain) diagnosis should include a complete anamnesis 
with performance status evaluation, laboratory test (includ-
ing CA19.9, reactive C protein and albumin levels) and in 
patients (≥ 70 years) frailty assessment.
Pathologic diagnosis is recommended in resectable 
disease and mandatory in borderline-resectable, locally 
advanced, and metastatic disease. Endoscopic ultrasonog-
raphy (EUS) and fine-needle aspiration (FNA) is the optimal 
technique to obtain pathologic diagnosis in localized dis-
ease and should be done before biliary stent placing. Tho-
racic and abdominal three-phase (pancreatic, arterial and 
portal) multidetector row computed tomography (MDCT) 
with 2–3 mm/thickness should be done in all cases for stag-
ing. Radiological report should include tumour vascular 
[venous (superior mesenteric vein and portal vein) and arte-
rial (celiac trunk, superior mesenteric artery and common 
hepatic artery)] involvement (see Table 1). Liver MRI, PET-
CT and laparoscopy, can complement staging.
Recommendations
Endoscopic ultrasonography (EUS) and fine needle 
aspiration (FNA) and thoracic and abdominal three-phase 
(pancreatic, arterial and portal) MDCT are the standard 




Twenty percent of patients have resectable disease based on 
MDCT and up-front surgical resection is indicated. Treat-
ment decision should be done only after careful evaluation 
in a multidisciplinary dedicated team. Surgical resection 
should be done preferably in high-volume Centers (recom-
mended > 20 pancreatic procedures/year) [8]. Pancreatic 
resections in specialized institutions have mortality rates 
below 5%.
Despite adequate oncologic resections, 76–82% of 
patients have positive margins (R1) if pathological spec-
imens are evaluated with standardized pathological 
procedures based on the Leeds Pathology protocol [9]. 
Recurrence rate at 2 year occurs in 70–80% of patients 
(either local and distant recurrences).
Recommendations
Surgical resection should be done preferably in high-vol-
ume specialized Centers. Pathological specimen should be 
evaluated with standardized pathological procedures based 
on the Leeds Pathology protocol (III, A).
CONKO-1 demonstrated superiority of gemcitabine over 
no therapy and fulfil primary end-point (increase 6 months 
median disease-free survival) and ESMO-MCBS [10] (7.5% 
3 year DFS in the control group and 23.5% in gemcitabine 
group).
The ESPAC-4 trial compared adjuvant gemcitabine 
vs. gemcitabine combined with capecitabine [11]. 3 year 
relapse-free survival was 20.9% in the gemcitabine group 
and 23.8% in the gemcitabine-capecitabine group with a HR 
0.86 that did not fulfill pre-defined primary end-point and 
ESMO-MCBS [10].
Recently the PRODIGE group compared adjuvant gem-
citabine vs. modified FOLFIRINOX (mFOLFIRINOX) in 
resected patients with ECOG PS 0–1 and CA19.9 below 
180 U/ml. The study fulfils pre-defined primary end-point 
(> 10% difference in PFS at 3 years) and ESMO-MCBS 
strict criteria (3 year PFS of 39.7% vs. 21.6% and a HR. 
0.58). Although patients under 79 years were included, 
only 20% of all patients have > 70 years. Frailty assessment 
is recommended, before treat patients over 70 years with 
mFOLFIRINOX [12].
Finally, PREOPANC study compared preoperative 
chemo-radiotherapy with gemcitabine vs. standard adju-
vant gemcitabine alone. This study included both, resect-
able and border-line resectable patients. The primary end-
point was designed to improve median survival (from 11 
to 17 months). Unfortunately, PREOPANC did not fulfill 
primary end-point and ESMO-MBSC criteria [13].
Recommendations
Adjuvant gemcitabine is recommended, in medium-
fit ECOG PS 0–1 patients older than 70  years. In 
patients < 70  years and ECOG PS 0–1 and fit patients 
between 70 and 80 years adjuvant therapy with mFOL-
FIRINOX could be considered standard treatment (I, A).
Borderline disease
Numerous non-randomized studies in patients with border-
line disease (BR) that have used different treatment regi-
mens with neoadjuvant chemotherapy or chemoradiation 
have managed to increase the resectability and R0 resection 
rate rates in BR. A korean randomized phase 2/3 trial test 
the neoadjuvant strategy in BR patients. The trial included 
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110 patients that were randomized to be treated with gem-
citabine-based neoadjuvant chemoradiation treatment ver-
sus surgery upfront. The trial demonstrated superior 2 years 
OS in the neoadjuvant arm (40.7% vs. 26.1%, HR 1.45, 
p = 0.0028). R0 resection rate was also significantly higher 
in the neoadjuvant group (51.8% vs. 26.1%, p = 0.004) [14]. 
There is limited evidence to recommend specific neoadju-
vant regimens off-study, and practices vary with regard to 
the use of chemotherapy and chemoradiation [15].
SWOG1505, a randomized phase II trial, demonstrated no 
difference between the perioperative treatment with mFOL-
FIRINOX or gemcitabine with albumin-bound paclitaxel 
[16].
Recommendations
1. Patients with BR should be included in Clinical Trials 
wherever possible.
2. FOLFIRINOX/mFOLFIRINOX and gemcitabine in 
combination with albumin-bound paclitaxel are two 
acceptable regimens to be used in the neoadjuvant strat-
egy (II, B).
3. Chemoradiotherapy with gemcitabine or capecitabine is 
an option (I, C).
Locally advanced disease
Owing to the difficulty of relying on strict criteria for 
unresectability, it should be recommended that all locally 
advanced pancreatic cancer (LAPC) are discussed by a mul-
tidisciplinary board, and that these evaluations are repeated 
after treatment induction to confirm definitive unresectabil-
ity. The possible role for surgery has been extended recently 
to some selected LAPC. A new classification may help the 
multidisciplinary boards to define the optimal strategy and 
the goal of the treatment. Type A are tumors that may be 
considered for surgery after induction chemotherapy, and 
type B are definitively unresectable tumors [17]. The objec-
tive in unresectable LAPC is to increase OS and quality of 
life, maintaining local control of the disease.
The initial approach is controversial. The LAP07 study 
showed no benefit in survival when comparing RT-CT 
vs. chemotherapy (CT) in patients with LAPC and con-
trolled after 4 months of induction QT treatment disease, 
but showed better local control and increased free survival 
progression [18]. The standard CT treatment in LAPC is 
gemcitabine, but the significant increase in efficacy with 
new schedules in metastatic disease (FOLFIRINOX for PS 
0–1 [19] and gemcitabine/albumin-bound paclitaxel for PS 
0–2 [20]) has lead to their use, also in LAPC, as a reason-
able alternative. However, we only have data from observa-
tional, pooled analysis or small phase II trials. The duration 
of the initial treatment is not established and depends on 
tolerability and tumor response. Using chemoradiotherapy 
consolidation in patients with response or stabilization after 
4–6 months of chemotherapy is an option to consider, vs. 
maintenance treatment with chemotherapy in patients with 
good PS. In this context, capecitabine showed a better toxic-
ity profile and efficacy than gemcitabine [21].
Recommendations
1. LAPC has to be discussed in a multidisciplinary tumor 
board in order to define its resectability (IV, A).
2. The standard treatment for LAPC is chemotherapy (I, 
A).
3. By extrapolation in the metastatic setting, FOL-
FIRINOX, mFOLFIRINOX or gemcitabine and albu-
min-bound paclitaxel represent acceptable treatments 
with higher response rate than gemcitabine (III, B).
4. After induction chemotherapy (between 4 and 6 months), 
consolidation with chemoradiotherapy is an option (III, 
C).
Metastatic disease
Taking into consideration the dismal prognosis of these 
patients, a clinical trial is always a good option if is available.
The chemotherapeutic regimen of FOLFIRINOX has 
been shown superior to gemcitabine monotherapy in PFS 
and OS [19]. In the MPACT phase III clinical trial, the 
combination of gemcitabine and nab-paclitaxel also dem-
onstrated superiority in terms of efficacy for metastatic 
pancreatic cancer (mPDAC) compared with gemcitabine 
monotherapy [20]. FOLFIRINOX and gemcitabine/ albu-
min-bound paclitaxel are both indicated in fit mPDAC 
patients with ECOG PS 0, 1 and ≤ 75 years old. In fit elderly 
patients (≥ 75 years) or patients with performance status 2, 
single-agent gemcitabine or gemcitabine and albumin-bound 
paclitaxel can be considered based on non-randomized data.
There are conflicting results with oxaliplatin-based chem-
otherapy in second-line treatment. Napoli trial demonstrated 
a superior OS, PFS, and RR in patients treated with 5-fluo-
rouracil and nal-IRI compared with patients treated with 
5-Fluorouracil alone [22]. This combination is an alterna-
tive for a fit patient who progresses to gemcitabine-based 
chemotherapy when it is available. Unfit patients can be 
treated with 5-fluorouracil in monotherapy (category 2B). 
Gemcitabine and albumin-bound paclitaxel is a second-line 
treatment option for fit patients after a 5-fluorouracil based 
chemotherapy, with no randomized data.
Pancreatic cancer patients with mutations in BRCA1 
or BRCA2 with a prevalence between 6 and 7% would 
be especially sensitive to platinum-based chemotherapy. 
In this population, we can use FOLFIRINOX, mFOL-
FIRINOX, gemcitabine with cisplatin or 5-FU and 
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cisplatin. The POLO trial evaluated Olaparib as main-
tenance therapy for individuals with germline BRCA1/2 
mutations and mPDAC that was stable or responded after 
at least 4 months of platinum-based chemotherapy. Olapa-
rib arm presented a superior PFS compared with placebo 
(7.4 m vs. 3.4 m), and some patients treated with Olapa-
rib presented a very durable response lasting in excess of 
2 years [23] (Fig. 1), however, in the POLO trial there is 
no impact in OS.
Patients with mPDAC and microsatellite instability 
(1–3%) treatment with checkpoint therapy can be considered 
when is available [24].
Recommendations
1. FOLFIRINOX/mFOLFIRINOX and/or Gemcitabine-
albumin-bound paclitaxel are standard first-line sched-
ules in metastatic disease in patients with ECOG/PS 0-1 
and younger than 75 years old (I, A).
2. In selected patients with ECOG 2 or older than 75 years 
old, gemcitabine and gemcitabine in combination with 
albumin-bound paclitaxel can be considered (II, B).
3. The combination of nal-IRI and 5-fluorouracil, is an 
alternative for a fit patient who progress to gemcitabine-
based chemotherapy, when it is available (I, A).
4. Gemcitabine and albumin-bound paclitaxel is a second 
line treatment option for fit patients after a 5-fluorouracil 
based chemotherapy (II, B).
5. Current data favor an approach of frontline platinum-
based chemotherapy followed by maintenance with 
Olaparib with mPDAC with germline BRCA 1 and 
BRCA2 mutations (I, A).
Supportive care
Early and systematic integration of palliative care in onco-
logical care improves clinical outcomes and quality of life 
(QoL) of patients with advanced pancreatic cancer [25]. 
In pancreatic cancer, there are five symptoms that must be 
emphasized: pain, jaundice, gastric outlet obstruction, and 
nutritional support.
Pain is often the major presenting symptom of the dis-
ease. We should indicate opioid medication, considering 
adjuvant medications in case of neuropathic pain with 
gabapentin, pregabalin, nortriptyline or duloxetine. In refrac-
tory patients celiac plexus neurolysis should be considered, 
percutaneously, surgically or under endosonographic guid-
ance. It has a success rate of 50–67%, and has demonstrated 
the superiority of pain relief over analgesic therapy, causing 
also fewer adverse effects than opioids [26].
Fig. 1  Frequent genomic altera-
tions in biliary tract cancers 
according to anatomic location. 
ICC intrahepatic cholangio-
carcinoma, ECC extrahepatic 
cholangiocarcinoma, GBC 
gallbladder cancer. The most 
clinically promising drug targets 
are highlighted in bold type
ICC
* IDH1/2 mutations (10-25%)
* FGFR1-3 fusions/amplifications
(10-15%)
* NTRK fusions (4%)
* ROS1 fusions
* BRAF V600 mutations ECC
* HER2/3 amplifications
(18%)
* Others: KRAS, TP53, SMAD4, ARID1A, 
GBC
* HER2/3 amplifications
* Others: KRAS, TP53 and PIK3CA mutations
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For palliation of obstructive jaundice, and its clinical 
consequences such as cholangitis, pruritus and impaired 
liver function, we recommend stent placement. Metal stents 
had a lower risk of recurrent obstruction than plastic stents, 
without differences in mortality or complications [27]. Plas-
tic stents had a lower duration of patency (above 3 months) 
than metal stents. The decision to use one versus another 
should be guided by expected length of survival, disease 
stage, ECOG, PS and comorbidities. The surgical bypass 
should only be reserved for those whose stent placement is 
not possible.
Gastric outlet obstruction, is a frequent symptom as the 
disease progresses and we recommend the placement of a 
stent at the duodenum over surgical approach, but the deci-
sion should be individualized considering life expectancy, 
disease stage, ECOG, PS and comorbidities.
All cancer patients should be screened regularly for the 
risk or the presence of malnutrition. In all patients—with the 
exception of end-of-life care—energy and substrate require-
ments should be met by offering in a step-wise manner nutri-
tional interventions from counseling to oral nutrition. How-
ever, the benefits and risks of nutritional interventions have 
to be balanced with special consideration in patients with 
advanced disease. Pancreatic exocrine insufficiency (PEI) is 
prevalent among patients with pancreatic adenocarcinoma in 
up to 64–100% of patients and contributes to fat malabsorp-
tion, which leads to maldigestion, steatorrhea, and weight 
loss. We recommend elastase-1 stool test to diagnose it. 
Enzyme replacement therapy improved survival in a recent 
population-based study and starting at doses of 75,000 IU 
daily are recommended [28].
Recommendations
1. Pain management with opioid therapy and celiac plexus 
neurolysis (I, A).
2. Obstructive jaundice and gastric outlet obstruction 
should be managed with stent placement (I, A).
3. Patients should be screened with elastase-1 stool test to 
diagnose PEI and receive enzyme replacement in case 
of insufficiency (I, A).
Surveillance
At least 80% of patients will develop local and/or distant dis-
ease recurrence after pancreatectomy, often within 2 years. 
Current evidence for recurrence-focused surveillance after 
pancreatic cancer resection is limited and contradictory. 
Although computed tomography positron emission tomog-
raphy and the serum CA 19.9 can detect preclinical recur-
rences, there is no evidence that treatment derived from early 
detection of recurrence increases survival.
Recommendations
There is no evidence that regular follow-up after initial 
therapy with curative intent prolongs survival (IV, D).
Biliary tract cancer
Introduction
Biliary tract cancers (BTC), including gallbladder cancer, 
intrahepatic, perihilar, and distal cholangiocarcinoma, are 
malignancies that arise from the epithelium of the biliary 
system. BTC represents a heterogeneous group of cancers 
with extensive biologic and genetic diversity. With early dis-
ease, surgical resection is the preferred option for all types; 
however, outcomes are poor.
Epidemiology and risk factors
Represent less than 1% of all cancers. In Spain, during 2019, 
2873 new BTCs were diagnosed representing an incidence 
of 6.1/100.000 [29]. Gallbladder cancer (GBC) is two times 
more frequent than intrahepatic or extrahepatic cholangio-
carcinomas; ampulla of Vater cancer is the less frequent 
type. Regarding primary liver cancers, intrahepatic cholan-
giocarcinoma is the second most type after hepatocellular 
carcinoma.
Etiologic studies on BTCs suggest that risk factors vary 
by anatomic origin site within the biliary tract. Moreover, 
incidence rates varied by sex, ethnicity, and age. GBC 
incidence rates were highest among women and older age 
groups since gallstones and subsequent cholecystitis are 
the primary risk incidence factors; approximately a third 
are attributable to obesity [30], other risk factors are: mul-
tiple pregnancies, family history of gallstones, low levels 
of physical activity, chronic infection by Salmonella (typhi 
and paratyphi) and Helicobacter (bilis and pylori) isolation. 
Only 1% of patients with gallstones develop GBC, suggest-
ing that any screening program should be targeted to higher-
risk groups. Nowadays, the incidence of GBC is decreasing 
in the Western world in relation to the increase in routine 
cholecystectomy [31].
Intrahepatic cholangiocarcinoma (ICC) presents higher 
incidence rates for males and older ages. It is associated 
with chronic inflammation of the biliary tree and hepatic 
parenchyma. Risk factors include chronic liver diseases and 
cirrhosis, biliary stones, liver infections (hepatitis B and C 
viruses, liver flukes), bile duct anomalies, some autoimmune 
diseases, obesity, diabetes, and smoking [32].
Extrahepatic cholangiocarcinoma (ECC) shares some 
risk factors with ICC. Nevertheless, a prior cholecystec-
tomy increases risk of ECC, but not of ICC. Choledochal 
cysts or bile duct anomalies have a 1–15% lifetime risk of 
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developing into GBC and cholangiocarcinoma. The risk of 
finding malignancy is higher when the diagnosis is made 
in adults or older age. Surgical resection, at the moment of 
diagnosis, is indicated to prevent malignancy.
Clinical diagnosis and staging
BTCs common classification is based on the anatomical site 
of origin: ECC are those CCAs arising from the common 
bile duct and its tributary branches; ICC (around ~ 30%) are 
those originating from the small ducts within the liver [33]. 
ECC can develop from the second-order of the bile ducts to 
the junction of the cystic duct and the common hepatic duct 
(perihilar, pECC, ~ 50%) or can arise from the common bile 
duct between the cystic duct origin and the ampulla of Vater 
(distal, dECC, ~ 20%).
Diagnosis of BTC is challenging, since, in most cases, 
patients can remain asymptomatic for a long period during 
early stage-disease or symptoms can be inspecific [34]. In 
ECC symptoms such as biliary obstruction and cholangitis 
are more frequent and precocious than in ICC and GBC. In 
consequence, more than 60% of BTC are diagnosed at an 
incurable advanced stage, and in less than 40% of all cases, 
a surgical resection is an option.
Early-stage disease is usually diagnosed through pathol-
ogy workup after routine surgery (cholecystectomy) or as an 
incidental finding during a routine radiology test.
Recommendations
1. The initial workup for those patients with suspicion of 
a BTC should include a blood test with liver function 
parameters (CEA and Ca 19.9 blood levels could be con-
sidered but not for diagnostic purposes) and a MDCT, 
with or without contrast, of the chest, abdomen, and pel-
vis (II, A) [35, 36].
2. A magnetic resonance cholangio-pancreatography 
(MR-CP) can assess the presence of satellite and distant 
lesions in the liver and invasion of biliary tract, major 
vessels, and nearby lymph nodes (II, A).
3. The role of PET scan has not been well established 
although may be useful for the detection of regional 
lymph node and distant metastases (III, C).
4. Assessment of hepatic reserve is mandatory in GBC and 
ICC when surgical resection is indicated. There are no 
pathognomonic imaging or pathologic features definitely 
associated with ICC. Nonetheless, LI-RADS can be use-
ful in distinguishing between ICC and hepatocellular 
carcinoma (HCC) (II, A).
5. For ICC patients undergoing resection biopsy is usually 
not necessary and an esophageal-gastroduodenoscopy 
and a colonoscopy could be recommended in some cases 
(IIIB, C).
6. In ECC endoscopic retrograde cholangiopancreatog-
raphy (ERCP) can be performed for complete imaging 
of the duct, brush cytology and stenting of obstruction 
when required (II, A).
Molecular pathology
Prevalent genomic alterations
Molecular cancer subtyping ultimate goal is to uncover 
potential targets amenable to become drug targets. Poten-
tially targetable genetic alterations occur in around 40–60% 
of BTC patients. Interestingly, these aberrations distribu-
tion is according to the anatomic location: in ICC are found 
mostly mutations in IDH1/2, BAP1, and ARID1A and FGFR 
rearrangements, while in ECC are more frequently found 
novel fusions in PRKACA/PRKACB and mutations in 
ARID1B (see Fig. 1) [37].
Alterations in DNA repair genes (MSH6, BAP1, ATM, 
MLH1, MSH2, BRCA1 and BRCA2) are relatively frequent: 
up to 16% of ICC and 45% of ECC display mutations in 
these genes [38].
In GBC the most frequently mutated genes include 
KRAS, TP53, ERBB3, and PIK3CA, whereas no mutations 
have been identified in IDH1 or IDH2.
The most frequent actionable alterations are IDH1/2 
gain of function mutations and FGFR2 fusions/rearrange-
ments, found in around 5–36% and 8–25%, respectively, of 
CC cases, mostly ICC. Amplification of HER2 (3–19%) is 
more frequent in GBC and ECC than in ICC.
BRAF (~ 5%) and BRCA2 mutations (~ 5%), fusion genes 
involving the genes NTRK1/2/3 (4%), ROS (8–9%), ALK 
(3%) and mismatch repair deficiency (dMMR) and/or high 
microsatellite instability (MSI-H) (3% in ICC, 2% ECC and 
6% in GBC) are quite rare in BTC [39].
The main targetable genetic aberrations (IDH1 and BRAF 
mutations, FGFR fusions, HER2 amplification) can be iden-
tified in circulating tumour DNA (ctDNA) in around 20% 
of BTC patients.
Molecular classification
Several molecular classifications of CC have been proposed 
(no molecular classification of GBC has been published thus 
far); nonetheless, none has yet been translated into the clini-
cal setting [35].
Recommendations
For patients with MMR/MSI-H tumors and BRCA 1/2 
mutations consider referral to genetic counseling and ger-
mline testing (III, B).




Surgical resection with free margins is the only curative 
treatment for BTC and is individualized based on tumour 
location. Only 20% of patients are candidates for curative 
surgery. The most relevant prognostic factors are margin 
status and lymph node metastases.
Adjuvant therapy Despite optimal surgical resection around 
60–70% BTC relapse. Since the last update of guideline 
three randomized phase III clinical trials have compared 
different chemotherapy regimens with observation follow-
ing surgery.
The BILCAP trial randomised 447 patients with ECOG 
performance status 0–2 to capecitabine 1250 mg/m2 twice 
daily on days 1–14 of a 3 week cycle, for 24 weeks or obser-
vation [40]. Capecitabine initiation was required within 
16 weeks of surgery. All types of BTC were included and 
the proportion of patients with N1 disease and R1 resection 
was 47% and 38% respectively. After a median follow up of 
60 months the primary endpoint was not met, mOS in the 
ITT population was 51.1 months in the capecitabine arm 
compared to 36.4 months in observation arm (HR 0.81, 95% 
CI 0.63–1.04; p = 0.097). In a protocol-specified sensitiv-
ity analysis, adjusting for nodal status, grade, and gender, 
a significant difference in OS was found (HR 0.71, 95% CI 
0.55–0.92; p = 0·010). This significant difference in OS was 
also described in the per-protocol analysis (HR 0.75, 95% 
CI 0.58–0.97; p = 0.028). The RFS was significant longer 
for capecitabine (24.4 months vs. 17.5 months, HR 0.75, 
95% CI 0.58–0.98; p = 0.033). The capecitabine dose is still 
a matter of debate and there is no consensus on the optimal 
dose.
There is a lack of RCT that assesses the benefit of adju-
vant radiotherapy. Several small trials [41] and meta-analysis 
[42] have suggested a survival benefit for chemoradiotherapy 
in eCCA and GBC with R1 resection or node-positive dis-
ease. The optimal fractionation schedule, dose and concur-
rent chemotherapy regimen is not established.
Neoadjuvant therapy is considered an experimental 
approach and should be used only in the context of a clini-
cal trial.
Recommendations
1. After curative resection of BTC, all patients should 
receive adjuvant therapy with capecitabine for 6 months 
(I, B).
2. Chemoradiotherapy may be considered in eCCC or GBC 
with R1 resection or BTC with node-positive disease (II, 
B).
Locally advanced disease
There is a lack of specifically dedicated RCT in unresectable 
locally advanced BTC. Systemic chemotherapy is the initial 
therapy of choice in this setting. The available evidence to 
support this recommendation comes from large randomized 
trials in the advanced disease that included a subgroup of 
patients with unresectable locally advanced tumours. The 
same therapeutic principles as described below in metastatic 
disease must be followed. The combination of cisplatin 
and gemcitabine is recommended whenever possible [43]. 
Other alternative regimens are based on fluoropyrimidines 
or oxaliplatin. After an initial period of at least, 3–4 months 
of systemic chemotherapy locoregional therapy can be dis-
cussed in a multidisciplinary tumour board. Different radio-
therapy techniques may be considered, including chemo-
radiation or stereotactic body radiation therapy (SBRT), 
depending on local availability. Also, radiofrequency abla-
tion, transarterial chemoembolization or radioembolisation 
with 90Y-microspheres may be an alternative in ICC. Reas-
sessment for resectability should be perform along therapy 
evolution. If tumor downstaging amenable to resection is 
achieved salvage surgery should be considered. Orthotopic 
liver transplantation should not be offered outside a clinical 
trial in high-volume and experienced transplant centers.
Recommendations
1. Upfront systemic chemotherapy is the treatment of 
choice in unresectable locally advanced BTC (I, B).
2. Locoregional therapy can be considered only after an 
initial period of at least 3–4 months of systemic chemo-
therapy (II, B).
Metastatic disease
Randomized controlled trials conducted in patients with 
advanced BTC demonstrated that systemic chemother-
apy prolongs survival over best supportive care [44, 45]. 
A pooled analysis of 104 trials including 2810 patients 
observed that gemcitabine and platinum-based regimens 
were associated with increased response and tumor control 
rates [46]. The improved efficacy of this chemotherapy regi-
men was further supported by the results of 2 randomized 
studies that established gemcitabine-cisplatin as the treat-
ment of choice in this setting [43, 47]. The ABC-02 study 
randomized 410 patients with advanced or metastatic chol-
angiocarcinoma, gallbladder, or ampullary cancer to receive 
gemcitabine with or without cisplatin. Overall survival (OS) 
was significantly longer in the cisplatin-gemcitabine group 
as compared to the gemcitabine group (median of 11.7 vs. 
8.1 months; HR 0.64; p < 0.001) [43]. Progression-free sur-
vival (PFS) (8 vs. 5 months, HR 0.63, p < 0.001) and tumor 
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control rate (81.4% vs. 71.8%, p = 0.049) also favored the 
cisplatin-gemcitabine group. A Japanese randomized phase 
II study reported similar results [47]. A meta-analysis of 
both trials indicated that benefit from the combination was 
independent of age, gender, tumor stage (locally advanced 
vs. metastatic), prior therapy (surgery vs. stent) and primary 
tumor site (intra- vs. extra-hepatic vs. gallbladder vs. ampul-
lary), although subgroups least likely to benefit were patients 
with ampullary tumors and poor performance status [48].
In the second-line setting, the ABC-06 randomized study 
also demonstrated a meaningful survival improvement with 
chemotherapy [49]. This trial randomized (1:1) 162 patients 
with advanced biliary tract cancer (BTC) and disease pro-
gression after prior treatment with cisplatin-gemcitabine to 
receive mFOLFOX or active symptom control (ASC) only. 
Median OS was 6.2 vs. 5.3 months for the mFOLFOX and 
ASC arms, respectively, and the 12 month OS-rate was 
25.9% vs. 11.4% (HR 0.69 adjusted for platinum sensitivity, 
albumin, and stage; p = 0.031).
More importantly, an improved understanding of the 
molecular bases of BTCs has enabled the identification 
of new targets for therapy with some recent encouraging 
results. In this context, a phase 3, randomized, double-
blind study (ClarIDHy) randomized (2:1) 185 patients with 
IDH1-mutant cholangiocarcinoma, previously treated with 
up to 2 treatment regimens, to receive a mutated IDH1 
inhibitor, ivosidenib (AG-120), or placebo [50]. PFS was 
significantly improved with ivosidenib compared with pla-
cebo (median of 2.7 vs. 1.4 months, HR 0.37; p < 0.0001). 
PFS at 6 and 12 months was 32% and 22% for ivosidenib-
treated patients, whereas there were no patients in the pla-
cebo group free from progression for 6 months or more. A 
trend towards an improved OS for the ivosidenib group was 
also observed (median of 10.8 vs. 9.7 months, HR 0.69, 
p = 0.060), although the cross-over design (57% of patients 
in the placebo group received ivosidenib upon progression) 
limited the ability of this trial to properly address this end-
point. Pemigatinib, a small molecule inhibitor of fibroblast 
growth factor receptor (FGFR) 1, FGFR2 and FGFR3, 
received accelerated approval in April 2020 in the USA for 
the treatment of previously treated advanced or metastatic 
cholangiocarcinoma with FGFR2 fusions [51]. This deci-
sion was based on results from a single-arm, phase 2 study 
(FIGHT-202) that enrolled 146 patients, 107 with FGFR2 
fusions or rearrangements, 20 with other FGF/FGFR altera-
tions, and 18 with no FGF/FGFR alterations. An objective 
response was observed in 38 patients with FGFR2 fusions 
or rearrangements (33%), including 3 complete responses. 
Most frequent grade 3–4 AEs were hypophosphataemia 
(12%), arthralgia (6%), stomatitis (5%), hyponatraemia (5%), 
abdominal pain (5%), and fatigue (5%). Several FGFR2 
inhibitors (infigratinib, TAS120, pemigatinib) are currently 
being evaluated in several ongoing randomized trials in 
advanced cholangiocarcinoma with FGFR rearrangements, 
versus cisplatin-gemcitabine in the first-line setting. Results 
are awaited with great interest as they may be practice-
changing in the near future.
BRAF mutations are encountered in 1–22% of intra-
hepatic cholangiocarcinomas. The ROAR basket trial 
(NCT02034110), included different tumors with BRAF 
V600E mutation that were treated with dabrafenib and 
trametinib [52]. Preliminary results in the BTC cohort (35 
patients, 80% pretreated with > 2 prior lines of chemother-
apy) were encouraging, with a response rate of 42% and 
a median survival of 11.7 months. Other ongoing trials 
(NCT01713972, NCT01902173) are also assessing dual 
MEK/BRAF inhibition in patients with BRAF‐mutant chol-
angiocarcinoma and shall help elucidate the role of this strat-
egy in these patients. Other potential targets currently being 
explored include Her2 amplification that is not uncommon 
in gallbladder cancer, but only case reports are available to 
date. Additional targeted approaches to be considered in cer-
tain subgroups of patients with advanced BTC include some 
recently approved drugs with molecularly-driven, tumor-
agnostic indications. Such is the case for pembrolizumab 
for tumors with microsatellite instability (< 1% of cholan-
giocarcinomas) or high tumor mutational burden (TMB > 10 
mutations/Mb) [53, 54], or TRK-inhibitors (larotrectinib or 
entrectinib) for tumors with NTRK rearrangements (< 5% 
of cholangiocarcinomas) [55, 56]. Only small numbers of 
BTC patients have been, however, included in these tumor-
agnostic trials. Overall, these results highlight the growing 
role and clinical relevance of tumor mutational profiling in 
the management of advanced BTC. However, none of these 
targeted therapies have been approved to date by the Euro-
pean Medicines Agency (EMA).
Recommendations
1. Gemcitabine and cisplatin is the treatment of choice as 
first-line therapy in fit patients with advanced BTC (I, 
A).
2. Oxaliplatin may be an alternative to cisplatin in patients 
with impaired renal function, and monotherapy with 
gemcitabine or fluoropyrimidines may be considered in 
frail patients (II, B).
3. mFOLFOX is the preferred treatment regimen in the 
second-line setting for fit patients with advanced BTC 
and no severe residual neurotoxicity from prior therapy 
(I, A). Fluoropyrimidines may be used as monotherapy 
in this setting in patients with significant cumulative 
neurotoxicity (III, C).
4. A comprehensive tumor molecular characterization shall 
be pursued where available in patients with advanced 
BTCs, as certain genetic alterations, such as IDH1 muta-
tions (I,A), FGFR2 fusions (II, B), BRAF mutations (II, 
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B), microsatellite instability (II, B), high-TMB (II, B), 
and NTRK rearrangements (II, B), among others, may 
benefit from specific targeted therapies. Enrolment of 
these patients in clinical trials is highly encouraged.
Supportive care
Early implementation of supportive care and active symp-
tom control is very relevant for patients with advanced, 
recurrent or metastatic disease as it has a major impact on 
patient’s quality of life and may also extend survival [50]. 
The focus should be placed in symptom management (pain, 
nausea, constipation, diarrhea, anorexia, weight loss, anxi-
ety, depression) and most common disease-related com-
plications, such as infections (i.e. cholangitis) and biliary 
or duodenal obstruction. Biliary drainage and endoscopic 
procedures are commonly required and may be planned in 
some patients with recurrent complications. A metal stent 
is preferred in patients with a life expectancy of > 3 months. 
Percutaneous transhepatic biliary drainage is recommended 
if endoscopic stenting is not feasible.
Follow‑up
There are currently no data to support a specific surveil-
lance schedule for BTCs treated with curative intent, nor 
is there any evidence to demonstrate that regular follow-up 
influences outcome. Nevertheless, most physicians do regu-
larly follow these patients, most commonly with 3-monthly 
visits during the first 2 years after therapy, and 6-monthly 
thereafter up to 5 years, including clinical examination, lab-
oratory tests (including LFTs and lactate dehydrogenase), 
tumors markers (CEA, CA19-9) and a body CT scan every 
3–6 months (IV, D).
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